(Q44140145)

English

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hans-Jürgen Möller

9

object named as

H J Möller

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

G J E Schmitt

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

E M Meisenzahl

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S Dresel

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

K Tatsch

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

B Rossmüller

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

T Frodl

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

U W Preuss

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

K Hahn

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

200-206

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

A new framework for investigating antipsychotic action in humans: lessons from PET imaging

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Implications of normal brain development for the pathogenesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-IBZM SPECT study

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600302

21 January 2018

Identifiers

10.1177/026988110201600302

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44140145&oldid=2107040279"